Neuronetics, Inc. (STIM)
NASDAQ: STIM · Real-Time Price · USD
2.280
-0.240 (-9.52%)
At close: Nov 7, 2025, 4:00 PM EST
2.290
+0.010 (0.44%)
After-hours: Nov 7, 2025, 7:18 PM EST
Neuronetics Revenue
Neuronetics had revenue of $37.30M in the quarter ending September 30, 2025, with 101.28% growth. This brings the company's revenue in the last twelve months to $129.87M, up 78.62% year-over-year. In the year 2024, Neuronetics had annual revenue of $74.89M with 4.96% growth.
Revenue (ttm)
$129.87M
Revenue Growth
+78.62%
P/S Ratio
1.02
Revenue / Employee
$181,387
Employees
716
Market Cap
156.15M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 74.89M | 3.54M | 4.96% |
| Dec 31, 2023 | 71.35M | 6.14M | 9.42% |
| Dec 31, 2022 | 65.21M | 9.89M | 17.89% |
| Dec 31, 2021 | 55.31M | 6.07M | 12.32% |
| Dec 31, 2020 | 49.24M | -13.41M | -21.41% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
STIM News
- 4 days ago - Neuronetics, Inc. (STIM) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 days ago - Neuronetics Reports Third Quarter 2025 Financial and Operating Results and Announces CEO Transition Plan - GlobeNewsWire
- 8 days ago - Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 9 days ago - Neuronetics Announces Three-Year Exclusive Partnership with Elite DNA Behavioral Health to Expand NeuroStar Access and Operational Excellence - GlobeNewsWire
- 18 days ago - Neuronetics to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call - GlobeNewsWire
- 7 weeks ago - New York State Medicaid Expands Coverage for TMS Therapy, Including NeuroStar® Advanced Therapy, to Treat Major Depressive Disorder (MDD) - GlobeNewsWire
- 3 months ago - Neuronetics, Inc. (STIM) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Neuronetics to Present at the Canaccord Genuity 45th Annual Growth Conference - GlobeNewsWire